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The activity of sulfono--AApeptide helical foldamers
that mimic GLP-1
Peng Sang1*, Zhihong Zhou2*, Yan Shi1, Candy Lee2, Zaid Amso2, David Huang2, Timothy Odom1,
Vân T.B. Nguyen-Tran2, Weijun Shen2†, Jianfeng Cai1†
Existing long -helix mimicking necessitates the retention of most natural amino acid residues to maintain their
biological activity. Here, we report the exploration of helical sulfono--AApeptides with entire unnatural backbones
for their ability to structurally and functionally mimic glucagon-like peptide 1 (GLP-1). Our findings suggest that
efficient construction of novel GLP-1 receptor (GLP-1R) agonists could be achieved with nanomolar potencies. In
addition, the resulting sulfono--AApeptides were also proved to display remarkable stability against enzymatic
degradation compared to GLP-1, augmenting their biological potential. This alternative strategy of -helix mimicking,
as a proof of concept, could provide a new paradigm to prepare GLP-1R agonists.
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a precise three-dimensional (3D) arrangement of their side functional groups and the helical pitch (5.1 versus 5.4 Å of -helix) (21),
leading to helical mimetics for targeting various -helix–interacting
proteins (Fig. 1, B and C) (23, 24). We were intrigued whether this
-helix–mimicking strategy could be used to mimic GLP-1, a very
long helical peptide. Functionally, it was unclear whether native
GLP-1 could be mimicked by sulfono--AApeptide-based helical
foldamers to form potent GLP-1R agonists. Could the critical residues
in native GLP-1 still play an important role in sulfono--AApeptides?
Additional questions could arise from the monolithic helix structure
of sulfono--AApeptides instead of peptide hybrids that may pose
extra challenges in interacting with GLP-1R. Without mimicking the
exact structure of GLP-1, would the sulfono--AApeptide be capable
of mimicking residues on multiple faces of GLP-1 helix? If successful,
it would provide a general strategy for the development of GLP-1R
agonists with chemically diverse functional groups based on sulfono-
-AApeptides. This mode of -helix mimicking would offer a new
paradigm for mimicking a myriad of long and complex helical peptides. Here, as a proof of concept, we report the first example of
foldameric peptidomimetics with entire unnatural residues for
GLP-1 mimicking.
RESULTS AND DISCUSSION

Design and biological activity of sulfono--AApeptides
Analysis of GLP-1/GLP-1R interaction reveals the critical residues
on GLP-1 that are responsible for tight binding to GLP-1R (4, 28).
Briefly, GLP-1 engages both its N-terminal domain and C-terminal
domain to interact with GLP-1R (Fig. 2A). Of the N-terminal domain, interaction of the polar residues H7, E9, T11, T13, and S17
with the seven-transmembrane domain of the receptor is the most
crucial (Fig. 2B). Truncated N-terminal domain GLP-1 peptide derivatives are agonists of GLP-1R at nanomolar concentrations in a
cyclic adenosine monophosphate (cAMP) assay (29). Sometimes,
such N-terminal truncation results in GLP-1R antagonists like
GLP-1(9-36) and exendin (9-39) (30, 31). In contrast, hydrophobic
residues F28 and L32 dominate the interaction of C-terminal -helix
of GLP-1 with the extracellular domain of GLP-1R. Cryo–transmission
electron microscopy studies indicate that the entire GLP-1 peptides
form a fairly straight -helix (4) instead of the G22-kinked helix (2),
suggesting that the kink at G22 may be due to the artifact of crystal
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The glucagon-like peptide 1 receptor (GLP-1R) (1–4) belongs to the
class B family of G protein–coupled receptors, and its incretin helical
peptide ligand GLP-1 (5–7) analogs are a promising drug candidate
for treating type 2 diabetes and obesity. However, the half-life of
GLP-1 is very short owing to rapid degradation by proteases (8–12).
Stabilizing GLP-1 is critical in the development of drugs to treat
diabetes. Side-chain cross-linking strategies have been used for conformational and metabolic stabilization of GLP-1 (13–15). However,
unintended contacts between the cross-links and GLP-1R may occur,
and the extent of proteolytic stabilization may be limited. It is conceivable that helical foldamers may provide an alternative strategy
to develop proteolytically stable GLP-1R agonists. Gellman et al.
(16, 17) reported beautiful work mimicking endogenous GLP-1
using conformationally constrained –amino acid residues to replace
some native  residues. The properly designed /-peptides displayed potent and prolonged activity in vivo. Goudreau et al. recently
reported the use of oligourea moieties in GLP-1 sequence to improve
the pharmaceutical properties of GLP-1 (18). Very recently, Levine et al.
(19) used the O-GlcNAcylation to GLP-1 to improve the stability
and in vivo activity. However, to the best of our knowledge, there is
no report on mimicking GLP-1 using entire unnatural backbones.
Mimicking a long -helix by unnatural peptidomimetics is highly
challenging owing to the difference in helicity between -helix and
helical foldamers yet appealing because complete unnatural backbone
could be more resistant to proteolysis than peptide hybrids.
Sulfono--AApeptides are recently introduced as a new class of
helical mimetics to address some enduring challenges in disrupting
-helix–mediated protein-protein interactions (20–27). As proteolytically stable peptidomimetics, sulfono--AApeptides exhibit unusual folding stability by adopting a series of helical structures with
well-defined hydrogen bonding patterns (21). Half of the residues
are introduced by sulfonyl chlorides in sulfono--AApeptides
(Fig. 1A), providing enormous chemical diversity. Furthermore, the
single crystal of the homogeneous sulfono--AA foldamers reveals
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Fig. 2. Structural analysis. (A) GLP-1 binds to GLP-1R (Protein Data Bank: 5VAI).
GLP-1 (7-36) is shown in blue and GLP-1R is represented in green cartoon. (B) The
helical domain of GLP-1 with critical residues showing as sticks. (C) Design of sulfono-
-AApeptide 3, with side chains mimicking the important residues in B. (The helix
was built on the crystal structure shown in Fig. 1. X, Y, and Z were designated to
indicate the face of residues on the helix, respectively.)

packing, which alleviates the challenge to mimic both N- and C-terminal
domains of GLP-1 simultaneously. A close view of the critical residues on GLP-1 (Fig. 2, B and C) reveals that H7 and T11 are on the
same face (X) of the helix, whereas F28 and L32 are on face Y; E9,
T13, and T11 are on face Z (X, Y, and Z are designated arbitrarily).
The preliminary analysis prompted our design of helical sulfono-
-AApeptides that potentially mimic GLP-1. As shown in Fig. 1
(D and E), chiral side chains and sulfonyl sides are distributed perfectly on four faces of helical scaffold, which could be used to mimic
critical residues of a native GLP-1 helical domain that interact with
GLP-1R. An intimate comparison suggests that side chains 1a and
3a could mimic residues on the X face of GLP-1, 11b and 13b could
potentially reproduce the functionality of residues on the Y face of
GLP-1, whereas 2a, 4a, and 6a were speculated to capture the ability
of E9, T13, and S17. This strategy led to the synthesis of series of
sulfono--AApeptides (Table 1, 3 to 16). For comparison purposes,
the native GLP-1 peptides were also synthesized (Table 1 and
Fig. 3, 1 and 2). The agonistic activity of these peptides was obtained
by measuring the receptor-mediated cAMP production in the
Chinese hamster ovary (Chok1) cells overexpressed with the hGLP-1R
(14, 32). The N-terminal capped and uncapped sulfono--AApeptides
3 and 4 contain desired side chains shown in Fig. 2C. The potency
of sulfono--AApeptide 3 is only two orders of magnitude lower
than that of GLP-1 1 (39.79 nM versus 0.11 nM) and ~10-fold
Sang et al., Sci. Adv. 2020; 6 : eaaz4988
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Circular dichroism measurements
To obtain further structural information and assess any conformational changes resulting from chemical modifications, we investigated
the secondary structure of homogeneous sulfono--AApeptides 3
to 16 and compared it with that of regular GLP-1 peptides 1 and 2.
Circular dichroism (CD) spectra were recorded between 190 and
270 nm in phosphate-buffered saline (PBS). As anticipated, the regular
GLP-1 peptides 1 and 2 adopted a right-handed helical conformation,
2 of 7
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Fig. 1. Chemical and crystal structure of sulfono--AApeptides. (A) The chemical
structure of sulfono--AApeptides. a and b denote the chiral side chain and the
sulfonamido side chain from the building block, respectively. (B) The crystal structure
of a sulfono--AApeptide; the cartoon structure was drawn by PyMoL. (C) Top view
of (B). (D and E) Schematic representation of distribution of side chains from sulfono-
-AApeptides. (D) Side view. (E) Top view, helical wheel.

lower than that of the capped GLP-1 2 (39.79 nM versus 3.33 nM,
respectively).
Our findings demonstrate that the design of full-length unnatural
peptidomimetics of GLP-1 is viable. The acetyl capped sulfono--
AApeptides displayed more potent agonistic effects than those with
an unmodified N terminus. The opposite effect was observed for the
regular GLP-1 peptides 1 and 2 (Table 1) where acetylation of the
N terminus reduced the agonistic potency of GLP-1 (16, 17). These
observations are consistent with different helical scaffolds in GLP-1
and the sulfono--AApeptides.
The functional group on position 6b is not highly critical, as the
change of methyl group (3 and 4) to a bulky anisole group only resulted in a fourfold decrease in binding affinity (Table 1 and Fig. 3, 5
and 6). Consistent with previous findings, the C-terminal domain is
less important than the N-terminal domain, as replacement of the
benzyl group on position 11b with a methyl group (7 and 8) only
resulted in a twofold decrease in activity compared with 5 and 6. It
is known that H7 is a critical residue for both receptor binding and
activation, and replacement of H7 with other aromatic groups, such
as Phe, virtually retains the same biological function of GLP-1, implying that aromaticity is critical at the N-terminal end (5). This is
similarly observed in sulfono--AApeptides (3 and 4). Substitution
of phenyl group for Lys side chain resulted in complete loss of activity
(9 and 10). As expected, the side chain on position 4a is highly critical.
Replacement of the 2-hydroxylpropyl group (the side chain to
mimic T13) with a benzyl group led to completely inactive sequences
11 and 12 (Table 1). It is intriguing that the first side chain preferred
is the aromatic group, as the longer sequences (13 to 16) completely
abolished the activity to activate cAMP release. Overall, these studies
revealed excellent structure-activity relationship for sulfono--
AApeptides to mimic GLP-1.
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Table 1. Structures of GLP-1(7-36) 1 and 2 and sulfono--AApeptides 3 to 16.

Peptide
1

Sequence
H-HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR-NH2

2

Ac-HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR-NH2

3

4

5

6
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Fig. 4. CD spectra of regular GLP-1 peptides 1 and 2 and sulfono--AApeptides
3 to 16 (100 M) measured in phosphate-buffered saline buffer.

whereas sulfono--AApeptides 3 to 16 reveal a strong cotton effect
with a positive maximum at around 208 nm, which is a characteristic
of a well-defined left-handed 414 helix (Fig. 4) (21) similar to previously reported homogeneous sulfono--AApeptides.
Stability study
A major problem limiting the use of GLP-1 analogs is their instability
due to the rapid degradation by proteases. Having found peptides 3
and 5 as the lead candidates based on their in vitro potency, we next
examined their enzymatic stability in comparison to the regular
GLP-1 peptides. The assays were performed by incubating 0.1 mg/ml
of peptides 3 and 5 and the regular peptides (1 and 2) with pronase
(0.1 mg/ml) in 100 mM ammonium bicarbonate buffer (pH 7.8)
at 37°C for 24 hours. High-performance liquid chromatography
(HPLC)–mass spectrometry was then used to analyze the stability
of the examined peptides. Unlike the regular GLP-1 peptides 1 and
2, which degraded completely with no intact peptide remaining,
sulfono--AApeptides 3 and 5 showed no detectable degradation
(Fig. 5A). These results display notable enhancement in the stability
of the sulfono--AApeptides against enzymatic degradation, augmenting their potential in therapeutic application. In addition, peptides
3 and 5 also showed remarkable stability in the presence of serum
for 24 hours (Fig. 5B), whereas peptides 1 and 2 had more than 60%
degradation under the same condition.
Oral glucose tolerance test
Next, we examined the blood glucose–lowering effect of the lead
sulfono--AApeptide 3 in comparison to native GLP-1 (Fig. 5, C and D).
The peptides were administered as single doses intraperitoneally to
C57BL/6 mice (overnight fasted; n = 6 per group) 60 min before a
glucose challenge. Two doses of sulfono--AApeptide 3 (4 and
40 mg/kg) were tested, and their efficacies were compared with native
GLP-1 (1 mg/kg) and vehicle control. At both doses, sulfono--
AApeptide 3 markedly decreased blood glucose levels at the time
points of 30 and 45 min with the dose of 40 mg/kg showing a more
Sang et al., Sci. Adv. 2020; 6 : eaaz4988
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CONCLUSION

In conclusion, we have developed a series of helical sulfono--
AApeptides that can structurally and functionally mimic residues
on the multiple faces of the -helical domain of GLP-1. These unnatural helical peptidomimetics display potent GLP-1R agonistic
activity in cell-based assay and oral glucose tolerance test (OGTT).
To the best of our knowledge, this work represents the first example
of foldameric peptidomimetics based on an entire unnatural backbone for GLP-1 mimicking. The excellent proteolytic stability of
these helical sulfono--AApeptides augments their biological potential.
This alternative strategy of -helix mimicking based on sulfono--
AApeptides provides a new paradigm for the preparation of GLP-1R
agonists. Exploration of this new strategy for the development of
more potent GLP-1R agonists is currently underway.
MATERIALS AND METHODS

Synthetic route of sulfono--AApeptides
The resin was swelled in N,N′-dimethylformamide (DMF) for 5 min
before use, followed by treatment with 20% piperidine/DMF solution (2 ml) for 15 min (×2) to remove an Fmoc (9-fluorenyl methoxycarbonyl) protecting group, and washed with DCM (×3) and DMF
(×3) afterward. A premixed solution of the Fmoc protected regular
amino acid/sulfono--AApeptide building block (2 eq), HOBt (4 eq),
and dissolved inorganic carbon (4 eq) in 2 ml of DMF was added to
the resin and shaken for 4 hours to complete the coupling reaction.
After washing with DCM and DMF, the resin was treated with 20%
piperidine/DMF solution for 15 min (×2). Another Fmoc protected
regular amino acid/sulfono--AApeptide building block (2 eq) was
attached on the resin following the procedure in the first coupling
step, and the Fmoc protecting group was removed after the coupling
reaction was done. The reaction cycles were repeated until the desired
sulfono--AApeptides were synthesized. For the capped sequence,
the N terminus was treated with acetic anhydride (1 ml) in pyridine
4 of 7
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Fig. 3. The agonist activities of GLP-1 (7-36) 1, its acylated version 2, and sulfono-
-AApeptides in the activation of GLP-1R using the cell-based HTRF assay.

pronounced effect, suggesting good pharmacodynamic effect in vivo
(Fig. 5C). A dose-related decrease in glucose clearance was observed
for 3 at both 4 and 40 mg/kg doses (Fig. 5D), consistent with the
abovementioned results of the cell-based assay.

SCIENCE ADVANCES | RESEARCH ARTICLE
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Fig. 5. Stability study and oral glucose tolerance test. (A) Analytic HPLC traces of 1, 2, 3, and 5 before and after incubation with Pronase (0.1 mg/ml). (B) The serum
stability of 1, 2, 3, and 5 was determined in 25% serum (v/v) at 37°C for 24 hours. (C and D) Pharmacodynamics of the GLP-1 mimic peptides in mice. A Single dose of
peptides was intraperitoneally administered into mice 1 hour before the oral glucose tolerance test (OGTT) (2 g/ kg glucose). (C) Blood glucose concentrations were
monitored for up to 120 min after oral glucose challenge. (D) Average area under the curve (AUC) calculated from OGTT data. Results show mean ± SEM of six mice per
treatment group; *P < 0.05 versus vehicle; t test.
Sang et al., Sci. Adv. 2020; 6 : eaaz4988
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(2 ml) (15 min × 2). The final sequence was cleaved using trifluoroacetic acid (TFA)/DCM (3 ml, 1:1, v/v) for 3 hours. The cleavage
solution was collected, and the beads were washed with DCM
(3 ml × 2). The solution was combined and evaporated under air
flow to give the crude product, which was analyzed and purified by
the Water Alliance HPLC System, at flow rates of 1 and 16 ml/min for
analytic and preparative HPLC, respectively. The gradient elution
method of 5 to 100% of solvent B [0.1% TFA in acetonitrile (MeCN)]
in A (0.1% TFA in H2O) over 50 min was performed. All the sulfono-
-AApeptides were obtained with a purity >95% after prep-HPLC
purification.

	[]  =   obs  / (n × l × c × 10)	
where obs is the measured ellipticity in millidegrees, while n is the
number of side groups, l is path length in centimeters (0.1 cm), and
c is the concentration of the sulfono--AA peptide in molar units.
In vitro GLP-1R activation assay
Chok1 cells overexpressed with GLP-1R were incubated with increased concentration of tested compounds for 30 min at 37°C. The
dose response is plotted as the HTRF ratio (EM665/615 nm). Data
points are the mean ± SEM of ≥3 independent experiments with
duplicate measurements for each experiment. Half maximal effective
concentration (EC50) values were calculated for each duplicate and
the mean values for cAMP EC50 ± SEM are reported in the table (15).
Enzymatic stability study
Lead compounds (3 and 5) and regular GLP-1 peptides (1 and 2)
(0.1 mg/ml) were incubated with protease (0.1 mg/ml) in 100 mM
ammonium bicarbonate buffer (pH 7.8) at 37°C for 24 hours
(23, 24). Then, the reaction mixtures were concentrated in a speed
vacuum at medium temperature to remove water and ammonium
bicarbonate. The resulting residues were redissolved in H2O/MeCN
and analyzed on a Waters Alliance HPLC system with a flow rate
of 1 ml/min and 5 to 100% linear gradient of solvent B (0.1% TFA
in MeCN) in A (0.1% TFA in H2O) over a duration of 50 min. The
ultraviolet detector was set to 215 nm.
Serum stability assays
The serum stabilities of peptides were determined in 25% (v/v)
aqueous pooled serum from human male AB plasma (Sigma-Aldrich,
Milan, Italy) (33). Peptides were dissolved in H2O/MeCN (70:30 v/v)
and then diluted in serum and incubated at 37°C for 24 hours. Fifty
microliters of solution was added to 50 l of MeCN on ice for 20 min
and then was centrifuged at 4°C for 15 min. The supernatant was
diluted with H2O (0.1% TFA) at a final concentration of 0.1 mg/ml
analyzed by reversed-phase HPLC. The amount of intact peptide was
Sang et al., Sci. Adv. 2020; 6 : eaaz4988

15 May 2020

OGTT and intraperitoneal glucose tolerance test
All animal care and experimental procedures were approved by the
Institutional Animal Care and Use Committee of California Institute for Biomedical Research (Calibr) and strictly followed the NIH
guidelines for humane treatment of animals. Female Charles River
C57BL/6 mice were fasted overnight and then intraperitoneally administered with 100 l of each peptide in PBS (pH 8.2) containing
1% dimethyl sulfoxide. After 60 min, mice were orally or intraperitoneally administered with 2 g of glucose solution per kilogram of
body weight and their tail blood glucose levels were measured before (0 min) and after glucose challenge for 2 to 3 hours.
SUPPLEMENTARY MATERIALS

Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/6/20/eaaz4988/DC1

REFERENCES AND NOTES

1. S. Runge, H. Thøgersen, K. Madsen, J. Lau, R. Rudolph, Crystal structure of the ligandbound glucagon-like peptide-1 receptor extracellular domain. J. Biol. Chem. 283,
11340–11347 (2008).
2. C. R. Underwood, P. Garibay, L. B. Knudsen, S. Hastrup, G. H. Peters, R. Rudolph,
S. Reedtz-Runge, Crystal structure of glucagon-like peptide-1 in complex
with the extracellular domain of the glucagon-like peptide-1 receptor. J. Biol. Chem. 285,
723–730 (2010).
3. A. Jazayeri, M. Rappas, A. J. H. Brown, J. Kean, J. C. Errey, N. J. Robertson, C. Fiez-Vandal,
S. P. Andrews, M. Congreve, A. Bortolato, J. S. Mason, A. H. Baig, I. Teobald, A. S. Doré,
M. Weir, R. M. Cooke, F. H. Marshall, Crystal structure of the GLP-1 receptor bound
to a peptide agonist. Nature 546, 254–258 (2017).
4. Y. Zhang, B. Sun, D. Feng, H. Hu, M. Chu, Q. Qu, J. T. Tarrasch, S. Li, T. Sun Kobilka,
B. K. Kobilka, G. Skiniotis, Cryo-EM structure of the activated GLP-1 receptor in complex
with a G protein. Nature 546, 248–253 (2017).
5. B. Manandhar, J.-M. Ahn, Glucagon-like peptide-1 (GLP-1) analogs: Recent advances,
new possibilities, and therapeutic implications. J. Med. Chem. 58, 1020–1037
(2015).
6. J. D. Drucker, The cardiovascular biology of glucagon-like peptide-1. Cell Metab. 24,
15–30 (2016).
7. D. J. Drucker, Mechanisms of action and therapeutic application of glucagon-like
peptide-1. Cell Metab. 27, 740–756 (2018).
8. K. Hupe-Sodmann, G. P. McGregor, R. Bridenbaugh, R. Göke, B. Göke, H. Thole,
B. Zimmermann, K. Voigt, Characterisation of the processing by human neutral
endopeptidase 24.11 of GLP-1(7–36) amide and comparison of the substrate specificity
of the enzyme for other glucagon-like peptides. Regul. Pept. 58, 149–156 (1995).
9. E. G. Siegel, G. Scharf, B. Gallwitz, R. Mentlein, C. Morys-Wortmann, U. R. Fölsch,
W. E. Schmidt, Comparison of the effect of native glucagon-like peptide 1 and dipeptidyl
peptidase IV-resistant analogues on insulin release from rat pancreatic islets. Eur. J. Clin. Invest.
29, 610–614 (1999).
10. E. G. Siegel, B. Gallwitz, G. Scharf, R. Mentlein, C. Morys-Wortmann, U. R. Fölsch,
J. Schrezenmeir, K. Drescher, W. E. Schmidt, Biological activity of GLP-1-analogues
with N-terminal modifications. Regul. Pept. 79, 93–102 (1999).
11. Q. Xiao, J. Giguere, M. Parisien, W. Jeng, S. A. St-Pierre, P. L. Brubaker, M. B. Wheeler,
Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo.
Biochemistry 40, 2860–2869 (2001).
12. L. Jessen, B. A. Aulinger, J. L. Hassel, K. J. Roy, E. P. Smith, T. M. Greer, S. C. Woods,
R. J. Seeley, D. A. D'Alessio, Suppression of food intake by glucagon-like peptide-1
receptor agonists: Relative potencies and role of dipeptidyl peptidase-4. Endocrinology
153, 5735–5745 (2012).
13. L. P. Miranda, K. A. Winters, C. V. Gegg, A. Patel, J. Aral, J. Long, J. Zhang, S. Diamond,
M. Guido, S. Stanislaus, M. Ma, H. Li, M. J. Rose, L. Poppe, M. M. Véniant, Design
and synthesis of conformationally constrained glucagon-like peptide-1 derivatives
with increased plasma stability and prolonged in vivo activity. J. Med. Chem. 51,
2758–2765 (2008).
14. E. N. Murage, G. Gao, A. Bisello, J.-M. Ahn, Development of potent glucagon-like
peptide-1 agonists with high enzyme stability via introduction of multiple lactam
bridges. J. Med. Chem. 53, 6412–6420 (2010).

6 of 7

Downloaded from https://www.science.org at University of South Florida on June 01, 2022

Circular dichroism
CD spectra were measured on an Aviv 215 CD spectrometer using
a 1-mm path length quartz cuvette, and compound solutions in PBS
buffer were prepared using dry weight of the lyophilized solid followed by dilution to give the desired concentration (100 M) and
solvent combination (23, 24). Ten scans were averaged for each sample, three times of independent experiments were conducted, and the
spectra were averaged. The final spectra were normalized by subtracting the average blank spectra. Molar ellipticity [] (deg·cm2·dmol−1)
was calculated using the equation

estimated by integrating the area under the corresponding elution
peak monitored at 215 nm.
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